<DOC>
	<DOCNO>NCT00302848</DOCNO>
	<brief_summary>EURAS multi-national , control , prospective , post-marketing , non-intervention cohort study new user drospirenone/ethinylestradiol ( DRSP/EE ) , levonorgestrel/ethinylestradiol ( LNG/EE ) oral contraceptive ( OCs ) routine condition medical practice seven European country . Baseline survey semiannual , active follow-up base postal questionnaire , validation report event woman 's treat physician . A multifaceted 4-level follow-up procedure establish ensure low loss follow-up rate . The objective study investigation incidence rare serious adverse event associate use new establish OCs , specifically incidence thromboembolic event .</brief_summary>
	<brief_title>European Active Surveillance Study ( EURAS )</brief_title>
	<detailed_description>Active surveillance use valid epidemiologic study design desirable new product , adverse effect may occur yet identify pre-marketing study . The EURAS study investigate safety oral contraceptive large cohort woman attend office prescribe physician . Its primary objective compare incidence rate adverse event user so-called new OCs user OCs . The study conduct phase IV commitment European Drug Authorities . The combined cohort include 50,000 60,000 woman recruit select set physician six European country . A total 1,500,000 cycle expect observed field work start early 2001 end early 2006 . The participate woman undergo baseline survey use self administered questionnaire describe baseline risk . Every six month fill questionnaire record complaints event use prescribe OC validate . A multifaceted 4-level follow-up procedure establish ensure low loss follow-up rate . Based experience obtain previous OC study complex source bias confound expect . Thus , multivariate method Cox regression use adjust confound . Regarding impact result public health , main emphasis absolute risk estimate .</detailed_description>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Progestins</mesh_term>
	<criteria>Women start OC use woman switch OCs Women willing participate active surveillance several year Women contraindication OC use</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Venous thromboembolism</keyword>
	<keyword>Drospirenone</keyword>
</DOC>